Market Cap 159.99B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 9.11
Forward PE 9.33
Profit Margin 12.42%
Debt to Equity Ratio 0.74
Volume 12,152,234
Avg Vol 44,625,605
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 84%
Beta 0.34
Analysts Sell
Price Target $28.60

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Loudermilk64
Loudermilk64 Aug. 25 at 4:45 PM
$PFE Going higher.
0 · Reply
RocroBio
RocroBio Aug. 25 at 4:43 PM
0 · Reply
RocroBio
RocroBio Aug. 25 at 4:43 PM
0 · Reply
JBS_84
JBS_84 Aug. 25 at 4:39 PM
$PFE completely depends on mrna. Compare our chart to mrna. They are trading exactly the same. That means hype. That means very risky.
0 · Reply
reyofhope
reyofhope Aug. 25 at 4:30 PM
$PFE live look bourla doing the Greek dance.
0 · Reply
Jtlo
Jtlo Aug. 25 at 3:58 PM
$PFE send it bourla
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Aug. 25 at 3:28 PM
$PFE - Bruv, bit odd, innit?
3 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 3:15 PM
$TNXP https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-2zlnl3uf4paw.html $PFE $SLS $IOVA
0 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 3:13 PM
$TNXP $PFE $SLS $IOVA https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-2zlnl3uf4paw.html
0 · Reply
zustrelaax
zustrelaax Aug. 25 at 3:10 PM
$PFE bring the sling shot missed last week on the $MRNA day
0 · Reply
Latest News on PFE
Pfizer Stock (PFE) Is a Buy despite Declining Revenue

2026-08-24T12:18:00.000Z - 1 day ago

Pfizer Stock (PFE) Is a Buy despite Declining Revenue


Pfizer (PFE) CEO Buys $1 Million of Company Stock

2026-08-14T18:45:04.000Z - 10 days ago

Pfizer (PFE) CEO Buys $1 Million of Company Stock


Pfizer price target lowered to $31 from $35 at Guggenheim

2026-08-07T11:40:49.000Z - 18 days ago

Pfizer price target lowered to $31 from $35 at Guggenheim


Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 21 days ago

Pfizer Earnings Call Transcript: Q2 2026


Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 21 days ago

Pfizer Earnings release: Q2 2026


Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 21 days ago

Pfizer Slides: Q2 2026


Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 21 days ago

Pfizer Quarterly report: Q2 2026


Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 21 days ago

Pfizer Post Loss on Higher Revenue


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 7 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 2 months ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 2 months ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 2 months ago

Pfizer's experimental drug misses main goal of lung cancer trial


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update


Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026


Loudermilk64
Loudermilk64 Aug. 25 at 4:45 PM
$PFE Going higher.
0 · Reply
RocroBio
RocroBio Aug. 25 at 4:43 PM
0 · Reply
RocroBio
RocroBio Aug. 25 at 4:43 PM
0 · Reply
JBS_84
JBS_84 Aug. 25 at 4:39 PM
$PFE completely depends on mrna. Compare our chart to mrna. They are trading exactly the same. That means hype. That means very risky.
0 · Reply
reyofhope
reyofhope Aug. 25 at 4:30 PM
$PFE live look bourla doing the Greek dance.
0 · Reply
Jtlo
Jtlo Aug. 25 at 3:58 PM
$PFE send it bourla
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Aug. 25 at 3:28 PM
$PFE - Bruv, bit odd, innit?
3 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 3:15 PM
$TNXP https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-2zlnl3uf4paw.html $PFE $SLS $IOVA
0 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 3:13 PM
$TNXP $PFE $SLS $IOVA https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-2zlnl3uf4paw.html
0 · Reply
zustrelaax
zustrelaax Aug. 25 at 3:10 PM
$PFE bring the sling shot missed last week on the $MRNA day
0 · Reply
Fire_Truck
Fire_Truck Aug. 25 at 3:07 PM
$TNXP $PFE $SLS $IOVA Is Tonmya a placebo drug. 🤔
2 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 3:02 PM
$TNXP I was happy to shift some of my $PFE profits into this last week after months of accumulating Pfizer under $25. We are nearing out break out moment.
0 · Reply
NorthOfSouth
NorthOfSouth Aug. 25 at 3:00 PM
$PFE RSI running a bit hot to take us to 30 today...prove me wrong
2 · Reply
doubleuptwice
doubleuptwice Aug. 25 at 2:59 PM
$PFE getting juicy 🍋
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 25 at 2:45 PM
$PFE is this real?
1 · Reply
Loudermilk64
Loudermilk64 Aug. 25 at 2:43 PM
$PFE over 30 next then?
0 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 2:28 PM
$TNXP Insiders been buying, tutes have been buying. Coverage expanding to 144M patients and growing, first FDA approved fibromyalgia drug in 15 years, RX weekly scripts have been growing. Why aren't you buying? $PFE $SLS $IOVA
3 · Reply
AnalyistKant
AnalyistKant Aug. 25 at 2:26 PM
$MRNA 👀 The $128 key support held, and Moderna is bouncing again. 📈 Barclays: PT raised $48$125 📈 Wolfe Research: upgraded Underperform → Peer Perform But the real catalyst remains: Moderna × Merck personalized cancer vaccine — Phase 3 Watch the levels: $145 reclaim → $155 breakout → $174–178 back in play. This isn’t just the COVID vaccine story anymore. The pipeline is evolving. $MRK $BNTX $PFE
0 · Reply
doubleuptwice
doubleuptwice Aug. 25 at 2:19 PM
$PFE springboard off 2816??
0 · Reply
Makingmillions192
Makingmillions192 Aug. 25 at 12:50 PM
$LEXX This industry is ripe for deals and acquisitions 🔥 Our time is coming ⏰ https://www.biopharmadive.com/news/roche-lean-mass-preservation-hanmi-obesity-deal/828579/ $RHHBY $LLY $NVO $PFE
0 · Reply
Reversal_Levels
Reversal_Levels Aug. 25 at 9:22 AM
Trade update. PFE is on pP signal (partial profits). We will use it to close this trade early at today's Open. Longer term investors can still hold (or sell half), but we try to show some different strategies. We can always pick $PFE back up if it comes down to test its RevL. In the chart we see how PFE is bumping into a double key price level, while PuLL and MoM look toppish. More: https://blog.reversallevels.com/2026/08/trading-journal-aug-25-2026.html (previous: https://x.com/lunatictrader1/status/2077710846394769855 )
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:15 AM
$PFE Pfizer PFE -0.36% ▼ stock is a Buy despite declining revenue, in my view. Shares of the drugmaker have been modestly ahead of the S&P 500 (SPX) in 2026, helped by an upwardly revised revenue guidance as well as a cheap valuation. With a 6.13% dividend yield and a 2026 non-GAAP P/E multiple of 9.43x, PFE stock is indeed one of the most compelling value opportunities in the large-cap healthcare space.
0 · Reply